71 results on '"Arhin, Francis"'
Search Results
2. In vitro Activity of Aztreonam-Avibactam and Comparators Against Metallo-β-Lactamase-Producing Enterobacterales from ATLAS Global Surveillance Program, 2016–2020
3. 2119. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2021
4. 2149. In vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant Enterobacterales With and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021
5. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020
6. 1720. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Urinary Tract Infections Collected During the ATLAS Global Surveillance Program, 2017-2020
7. 1717. In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2020
8. Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019
9. 13: IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND AZTREONAM-AVIBACTAM AGAINST CARBAPENEM-NONSUSCEPTIBLE ENTEROBACTERALES ISOLATES COLLECTED IN ASIA/PACIFIC FROM 2017–2020 AS PART OF THE ATLAS GLOBAL SURVEILLANCE PROGRAm
10. 11: IN VITRO ACTIVITY OF AZTREONAM-AVIBACTAM AGAINST ENTEROBACTERALES ISOLATES THAT CARRY METALLO-β-LACTAMASES COLLECTED IN THE ASIA/PACIFIC REGIONAS A PART OF THE ATLAS GLOBAL SURVEILLANCE PROGRAM FROM 2015–2020
11. Antimicrobial Activity of Ceftazidime–Avibactam and Comparators Against Fluoroquinolone-Resistant Klebsiella pneumoniae Collected Globally from Antimicrobial Testing Leadership and Surveillance: 2018–2019
12. In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019
13. Critical Factors of Digital Supply Chains for Organizational Performance Improvement
14. 1225. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales Collected from Geriatric Patients in ICU and non-ICU wards, ATLAS Surveillance Program 2016-2019
15. 1252. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Bloodstream Infections collected during the ATLAS Global Surveillance Program, 2015-2019
16. 1231. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Lower Respiratory Tract Infections Collected During the ATLAS Global Surveillance Program, 2017-2019
17. 1265. In Vitro Activity of Aztreonam-Avibactam against Klebsiella pneumoniae Isolates Analyzed by Epidemic Lineage and Hypervirulence Factors Collected in China as Part of the ATLAS Global Surveillance Study in 2019
18. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
19. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017
20. 1567. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Multidrug-Resistant Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2016-2018
21. Analyzing the impact of environmental collaboration among supply chain stakeholders on a firm’s sustainable performance
22. Supplier sustainability performance evaluation and selection: A framework and methodology
23. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model
24. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci
25. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection
26. Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci
27. Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections
28. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015
29. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus
30. Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci
31. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus
32. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State
33. Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility
34. Antibacterial Activity of Oritavancin and Daptomycin Against Clinical Isolates of Vancomycin-Resistant Enterococcus faecium in In Vitro Pharmacokinetic/Pharmacodynamic Models
35. Assessment of the Propensity of Oritavancin to Induce Susceptibility Changes Among Staphylococcus aureus Nasal Carriage Isolates in a Phase 2 study in Patients with Acute Bacterial Skin and Skin Structure Infections
36. Assessment of Oritavancin Activity in Combination with Beta-Lactams against Vancomycin-Resistant Enterococci
37. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011–2014
38. Use of In Vitro Vancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide
39. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene
40. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)
41. Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection
42. Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci
43. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus
44. Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing
45. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005–2008
46. Assessment of Oritavancin Serum Protein Binding across Species
47. Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis
48. Characterization of the In Vitro Activity of Novel Lipoglycopeptide Antibiotics
49. Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates
50. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.